BioMarin (BMRN) Pharmaceutical announced that the U.S. FDA has accepted for Priority Review the company’s Palynziq supplemental Biologics License Application to expand treatment to include adolescents aged 12-17 with phenylketonuria. The FDA has set a Prescription Drug User Fee Act target action date of Feb. 28, 2026
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth
- BioMarin’s Earnings Call: Growth Amid Challenges
- BioMarin price target lowered to $80 from $90 at Truist
- BioMarin price target lowered to $66 from $70 at RBC Capital
- BioMarin Pharmaceutical: Undervalued Growth Potential and Strategic Positioning Support Buy Rating